PTO/SB/30 (07-09)
Approved for use through 07/31/2012 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Astrof 0995 contrating on the Paperwork Reduction Reduct	ed to respond to a collection of inform	nation unless it contains a v
Request	Application Number	09/676,374
for Continued Examination (RCE)	Filing Date	09-29-2000
Transmittal	First Named Inventor	Ernest H. Zerenner
Address to: Mail Stop RCE	Art Unit	3696
Commissioner for Patents P.O. Box 1450	Examiner Name	Felten, D.
Alexandria, VA 22313-1450	Attorney Docket Number	POPT-0004
This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Returning https://doi.org/10.114/10		
 Submission required under 37 CFR 1.114] Note: If the RCE is proper, any previously filed unentered amendments and anti-induscribentesides this his RCE will be entered in the order in which they were filed unless applica applicant doesnipt orbidable have any previously filed unentered amendment(s) entered, applicant must amendment(s). 		
a. Défécéoastjon.umajtisé. If a final Office action is outstanding, any amendments filed after the final considered as a submission even if this box is not checked.		
i. Consider the arguments in the Appeal Brief or Reply Brief previously filed on		
ii. Other		
b. 🗹 Enclosed		
I. ☐ Amendment/Reply iii. ✓ Information Disclosure Statement (IDS)		
ii. Affidavit(s)/ Declaration(s) iv. Other		
2. Miscellaneous		
Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a a		
b. Other		
3. Fees The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filled.		
The Director is hereby authorized to charge the following fees, any underpayment of fees, or credit any overpayments, to Deposit Account No. 23-3050		
i. RCE fee required under 37 CFR 1.17(e)		
ii. Extension of time fee (37 CFR 1.136 and 1.17)		
iii. Other		
b. Check in the amount of \$		
c. Payment by credit card (Form PTO-2038 enclosed)		
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.		
	NT, ATTORNEY, OR AGENT R	
Signature /John E. McGlynn/	Da	
Name (Print/Type) John E. McGlynn	re	gistration No. 42,863
CERTIFICATE OF MAILING OR TRANSMISSION		
Il hberdisjeledflydstagferie Entskripponderitinist einspitagerslied with the United States Postal Service w intuitivesteet basektildstags/REU.Schratenkswizirif for Betentis, P. O. Box 1459, Alexandria, VA 22313-1450 or Office on the date shown below.		
Signature		
Name (Print/Type)	Date	
Thiskatalisebene littigitimen pilonid svirigitimen licinid svirigitimen licinid licini	on is required to obtain o	

tespoolesspansiospilinisation (Central dell'amplitudes) avcomp priyos 0. S.C. 122 and 37 CFR 1.11 and 1.14. Initiality application purpolary injusticable ellegation control to the USPTO. Time will hadden escale to the USPTO and the USPTO. Time will hadden escale that the USPTO and the USPTO. Time will hadden escale that the USPTO and the USPTO. Time will hadden escale that the USPTO and the USPTO. The will hadden escale that the USPTO and the USPTO. The will hadden escale that the USPTO and the USPTO. The will hadden escale that the USPTO and the USPTO. The WILL T

ADDRESS SEND TO: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Instruction Sheet for RCEs

(not to be submitted to the USPTO)

NOTES:

Ame®C⊞ingnot a new application, and filing an RCE will not result in an application being accorded date.

Filing Qualifications:

The application must be a utility or plant application filed on or after June 8, 1995. The application cannot be a provisional application, a utility or plant application filed before June 8, 1995, a design application, or a patent under reexamination. See 37 CFR 1.114(e).

Filing Requirements:

Prosecution in the application must be closed. Prosecution is closed if the applicat ion is under appeal, or the last Office betiapplications[exploan3/1666e of allowance, or an action that otherwise closes prosecution in t action under Expare Quayle). See 37 CPR 1.14(b).

A submission and a fee are required at the time the RCE is filed. If reply to an Office action under 35 U.S.C. 132 is uintertainting (183;CFRe \$\frac{1}{2}\text{filed}\text{.filed}\text{.fired}\text{

WARNINGS:

Request for Suspension of Action:

All RCE filing requ irements must be met before suspension of action is granted. A request for a suspension of largioritheder 37 CFR 1.103(c) does not satisfy the submission requirement and does not permit the fil required submission to be suspended.

Improper RCE will NOT toll Any Time Period:

Before Appeal - If the RCE is im proper (e.g., prosecution in the application is not closed or the submission or fee has not been filed) and the application is not under appeal, the time period set forth in the last Off ice action will continue to run and the application will be ab andoned after the statutory time period has expired if a reply to the Office action is not timely filed. No additional time will be given to correct the improper RCE.

Under Appeal - If the RCE is improper (e.g., the submission or the fee has not been filed) and the application is under appeal, the improper RCE is effective to withdraw the appeal. With drawal of the app eal results in the allowance or abandonment of the application depending on the status of the claims. If there are no allowed elpiassedthacispilication is abandoned. If there is at least one allowed claim, the application will be on the allowed claim(s). See MPEP 1215.01.

See MPEP 706.07(h) for further information on the RCE practice.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that; (1) the general authority for the collastiancy of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is and (3) the principal purpose for which the information is used by the U.S. Patient and Trademark Office is to process and/or examine your submission related to a patient application or patient. If you furnish the requested information, the U.S. Patient and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandomment of the apolication or expiration of the patient.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S. 652a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, oursuant to 5 U.S.C. 552/ml.
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or reculation.